Clearance Summary
PROSIGNA(TM) BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY received FDA 510(k) clearance under submission number K130010, sponsored by Nanostring Technologies. The device was reviewed via the Traditional premarket notification pathway and assigned to the Immunology review panel. The statutory decision date of record is 2013-09-06.
- Submission: K130010
- Applicant / Sponsor: Nanostring Technologies
- Clearance pathway: Traditional
- Review panel: Immunology
- Device class: Class II
- Regulation citation: 21 CFR 866.6040
- Decision date: 2013-09-06
Classification & Regulation
This clearance is catalogued under FDA product code NYI and 21 CFR 866.6040, within the Immunology review panel as a Class II device.